BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 33827891)

  • 1. Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
    Taki M; Abiko K; Ukita M; Murakami R; Yamanoi K; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M
    Clin Cancer Res; 2021 Sep; 27(17):4669-4679. PubMed ID: 33827891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
    Erin N; Grahovac J; Brozovic A; Efferth T
    Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
    Liao TT; Yang MH
    Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
    Cai J; Cui Y; Yang J; Wang S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay of Immunometabolism and Epithelial-Mesenchymal Transition in the Tumor Microenvironment.
    Chou MY; Yang MH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype.
    Sahoo S; Nayak SP; Hari K; Purkait P; Mandal S; Kishore A; Levine H; Jolly MK
    Front Immunol; 2021; 12():797261. PubMed ID: 34975907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.
    Chockley PJ; Keshamouni VG
    J Immunol; 2016 Aug; 197(3):691-8. PubMed ID: 27431984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNAIL1: Linking Tumor Metastasis to Immune Evasion.
    Tang X; Sui X; Weng L; Liu Y
    Front Immunol; 2021; 12():724200. PubMed ID: 34917071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance.
    Singh D; Siddique HR
    Cancer Metastasis Rev; 2024 Mar; 43(1):155-173. PubMed ID: 37775641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the role of EMT in tumor immune escape.
    Terry S; Savagner P; Ortiz-Cuaran S; Mahjoubi L; Saintigny P; Thiery JP; Chouaib S
    Mol Oncol; 2017 Jul; 11(7):824-846. PubMed ID: 28614624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1.
    Hu B; Tian X; Li Y; Liu Y; Yang T; Han Z; An J; Kong L; Li Y
    Cancer Med; 2020 Apr; 9(8):2686-2697. PubMed ID: 32077634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
    Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
    Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.
    Drak Alsibai K; Meseure D
    Dev Dyn; 2018 Mar; 247(3):405-431. PubMed ID: 28691356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry.
    Bonavida B; Baritaki S
    Crit Rev Oncog; 2011; 16(3-4):211-26. PubMed ID: 22248055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
    Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
    Front Immunol; 2021; 12():693881. PubMed ID: 34552581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
    Lou Y; Diao L; Cuentas ER; Denning WL; Chen L; Fan YH; Byers LA; Wang J; Papadimitrakopoulou VA; Behrens C; Rodriguez JC; Hwu P; Wistuba II; Heymach JV; Gibbons DL
    Clin Cancer Res; 2016 Jul; 22(14):3630-42. PubMed ID: 26851185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.